No Data
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeuticsto Buy
Atossa Therapeutics Analyst Ratings
Express News | Atossa Therapeutics To Present Data Describing the Discovery of Compounds That May Be Synergistic With (Z)-Endoxifen And That Could Potentially Be Used in Combinations For The Treatment Of Breast Cancer. The Data Will Be Presented In A Poster At The...
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic With (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
No Data
